Alogliptin; Pioglitazone; Placebo
Проводит Takeda
Страница компанииA Multicenter, Double-Blind Study to Determine the Efficacy and Safety of SYR-322 Plus Pioglitazone HCl (Actos®), SYR-322 Alone or Pioglitazone HCl Alone in Subjects With Type 2 Diabetes
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00395512/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–80 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 655 чел. во всех странах исследования.
- Плановая дата окончания (02.2008) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 9 · невключение: 22
Критерии включения
- Historical diagnosis of type 2 diabetes.
- Failed treatment with diet and exercise for at least 2 months prior to Screening.
- Is experiencing inadequate glycemic control as defined as glycosylated hemoglobin concentration between 7.5-11%, inclusive.
- Has received any antidiabetic therapy for less than 7 days within 3 months prior to Screening.
- Has a body mass index greater than or equal to 23 kg/m2 and less than or equal to45 kg/m2.
- Fasting C-peptide greater than or equal to 0.8 ng per mL.
- Regular use of other, non-excluded medications is allowed if participant is on a stable dose for at least 4 weeks prior to Screening.
- Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.
- Must be willing and able to monitor their blood concentrations with a home glucose monitor.
Критерии невключения
- Systolic blood pressure greater than or equal to 160 mmHg and diastolic blood pressure greater than or equal to 100 mmHg.
- Hemoglobin less than or equal to 12 g per dL for males and less than or equal to 10 g per dL for females.
- Alanine aminotransferase greater than or equal to 2.5times the upper limit of normal.
- Serum creatinine greater than 2.0 mg per dL.
- Thyroid stimulating hormone level greater than the upper limit of normal range.
- Major illness or debility that in the investigator's opinion prohibits the subject from completing the study.
- Urine albumin to creatinine ratio of greater than 1000 ug per mg at Screening. If elevated, the subject may be rescreened within 1 week.
- History of cancer, other than squamous cell or basal cell carcinoma of the skin, that has not been in full remission for at least 5 years prior to Screening
- History of laser treatment for proliferative diabetic retinopathy within 6 months prior to Screening.
- History of gastroparesis.
- Has New York Heart Association Class I to IV heart failure regardless of therapy.
- History of coronary angioplasty, coronary stent placement, coronary bypass surgery, or myocardial infarction within 6 months prior to Screening.
- History of any hemoglobinopathy that may affect determination of glycosylated hemoglobin.
- History of infection with hepatitis B, hepatitis C, or human immunodeficiency virus.
- History of a psychiatric disorder that will affect participant's ability to participate in the study.
- History of angioedema in association with use of angiotensin-converting enzyme inhibitors or angiotensin-II receptor inhibitors.
- Any alteration in angiotensin-II receptor inhibitors within 2 months prior to Randomization, if applicable.
- History of alcohol (defined as regular or daily consumption of more than 4 alcoholic drinks per day) or substance abuse (defined as illicit drug use) within 2 years prior to Screening.
- Received any investigational drug within 30 days prior to Screening or a history of receipt of an investigational antidiabetic drug within 3 months prior to Screening.
- Previously participated in an investigational study of SYR-322.
- Glycosylated hemoglobin concentration between 7.5-11%, inclusive, and a fasting plasma glucose less than 310 mg per dL.
- At least 75% compliant with the single-blind placebo regimen during the run-in/stabilization period.
Источник: ClinicalTrials.gov, NCT00395512 · запись обновлена в реестре 27 марта 2013.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 40
- Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c) — Baseline and Week 26
Цель исследования
The purpose of this study is to evaluate the combination of alogliptin, once daily (QD), and pioglitazone in patients with type 2 diabetes mellitus who are inadequately controlled with diet and exercise alone.
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00395512 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.